Ulcerative Colitis
📧 Sign up to get email alerts when something new happens for Ulcerative Colitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-01-25Clinical Trial Update: National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life
A national observational study assessing the real-world use of Inflectra (infliximab biosimilar) across multiple inflammatory diseases compl…
-
CLINICAL_TRIALS trial_result · 2023-01-18Clinical Trial Update: Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease
A completed clinical trial assessing healthcare resource use, mental health problems, and infections in people with inflammatory bowel disea…
-
CLINICAL_TRIALS trial_result · 2023-01-13Clinical Trial Update: Study of OST-122 in Patients With Moderate to Severe Ulcerative Colitis [Phase 1, Phase 2]
Clinical trial update for OST-122 in moderate to severe ulcerative colitis completed phases 1 and 2.
-
CLINICAL_TRIALS trial_result · 2022-12-21Clinical Trial Update: Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis [Phase 3]
Phase 3 trial comparing etrasimod to placebo as induction therapy in moderately to severely active ulcerative colitis has completed with res…
-
CLINICAL_TRIALS trial_result · 2022-12-20Clinical Trial Update: Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis [Phase 3]
A Phase 3 clinical trial comparing etrasimod to placebo in moderately to severely active ulcerative colitis has completed; results were post…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-12-13FDA Approved: IDACIO — Original Application (Fresenius Kabi USA, LLC)
FDA approved IDACIO (adalimumab-afcf) from Fresenius Kabi USA, LLC as a biosimilar to adalimumab (Humira) under an original Biologics Licens…
-
CLINICAL_TRIALS trial_result · 2022-12-05Clinical Trial Update: ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis. [Phase 2]
Phase 2 trial evaluating Alicaforsen (ISIS 2302) vs placebo in mild to moderate active Ulcerative Colitis completed.
-
CLINICAL_TRIALS trial_result · 2022-12-05Clinical Trial Update: ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis [Phase 2]
Phase 2 trial investigating Alicaforsen (ISIS 2302) in mild to moderate active ulcerative colitis has completed.
-
CLINICAL_TRIALS trial_result · 2022-11-25Clinical Trial Update: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis [Phase 3]
Phase 3 maintenance trial results for mirikizumab in adults with moderately to severely active ulcerative colitis have been completed and po…
-
CLINICAL_TRIALS trial_result · 2022-11-22Clinical Trial Update: A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis. [Phase 2]
Phase II trial in adults with moderate to severe active ulcerative colitis completed; results posted.
-
FDA approval · 2022-11-16FDA Approved: LIALDA — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for LIALDA (mesalamine) from Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2022-11-16FDA Approved: DIPENTUM — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Dipentum (olsalazine sodium) submitted by Viatris Specialty LLC.
-
FDA label_change · 2022-11-16FDA Approved: MESALAMINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for mesalamine from Teva Pharmaceuticals USA to update the product labeling.
-
FDA approval · 2022-11-16FDA Approved: AZULFIDINE EN-TABS — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for Azulfidine En-Tabs (sulfasalazine) filed by Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2022-11-16FDA Approved: MESALAMINE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for MESALAMINE from ANI Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2022-11-15Clinical Trial Update: Efficacy & Safety of TD-1473 in Ulcerative Colitis [Phase 2, Phase 3]
Phase 2/3 trial of TD-1473 for ulcerative colitis was terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2022-11-07Clinical Trial Update: Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD) [Phase 2]
Phase 2 clinical trial update for AMT-101 in ulcerative colitis; efficacy and safety data are not specified in the provided snippet.
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: Efficacy and Safety of Oral BT-11 in Ulcerative Colitis [Phase 2]
Phase 2 trial results for oral BT-11 in ulcerative colitis have been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-11-02Clinical Trial Update: TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study [Phase 2, Phase 3]
Long-term safety study of TD-1473 in ulcerative colitis was terminated; results posted in 2022.
-
FDA approval · 2022-10-28FDA Approved: MESALAMINE — Original Application (Alembic Pharmaceuticals Limited)
FDA approved the original application for a generic MESALAMINE product by Alembic Pharmaceuticals Limited.
-
CLINICAL_TRIALS trial_result · 2022-10-26Clinical Trial Update: Lactobacillus Rhamnosus GG (ATCC 53103) in Mild-moderately Active UC Patients [Phase 1, Phase 2]
Phase 1/2 trial updating on Lactobacillus rhamnosus GG (ATCC 53103) in patients with mild-to-moderate ulcerative colitis has completed.
-
CLINICAL_TRIALS trial_result · 2022-09-14Clinical Trial Update: Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET) [Phase 2]
Phase 2 trial update on AMT-101 in combination with adalimumab in ulcerative colitis completed.
-
CLINICAL_TRIALS trial_result · 2022-08-24Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis [Phase 2]
Phase 2 clinical trial evaluating tilpisertib for adults with moderately to severely active ulcerative colitis has been terminated; results …
-
FDA approval · 2022-07-27FDA Approved: MESALAMINE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for mesalamine from Zydus Lifesciences Limited.
-
CLINICAL_TRIALS trial_result · 2022-07-21Clinical Trial Update: Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis [Phase 2]
Phase 2 trial comparing oral PF-06651600, PF-06700841, and placebo in moderate to severe ulcerative colitis completed with posted results.